Access cutting-edge leiomyosarcoma treatment through this clinical trial at a research site in Nashville. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Nashville location
Preparing your pre-screening questions…
Access leiomyosarcoma specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related leiomyosarcoma treatment provided free
Check if you qualify for this leiomyosarcoma clinical trial in Nashville, TN
No-Cost Study Care
Local to Nashville
Convenient for TN residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Leiomyosarcoma (LMS) is one of the most prevalent soft tissue sarcomas (STS) and can occur in various sites including soft tissue, uterus and retroperitoneal large vessels. Metastatic disease occurs in approximately 50% of patients diagnosed with leiomyosarcoma and prognosis is poor in setting of metastatic disease. A minority of patients benefit from treatment with chemotherapy and early biomarkers of benefit from treatment are lacking. A biomarker of tumor response and patient survival benefit from chemotherapy early in the course of chemotherapy would be of significant impact in treatment planning. Circulating tumor DNA (ctDNA) is present in blood of patients with advanced/metastatic cancer and may serve as biomarker of tumor response to chemotherapy. Blood samples will be collected prior to and during and chemotherapy, and analyzed for ctDNA and for mutations in genes that are associated with increased risk of developing sarcoma. Tumor tissue will be collected and analyzed for changes in genes. Digital images of the sarcoma from CT or MRI scans obtained during treatment will be obtained for advanced radiomic analysis. Study participants will be asked to complete a questionnaire on attitudes and understanding of genetics and genetic testing.
Sponsor: University of Michigan Rogel Cancer Center
Yes, this clinical trial (NCT05653388) has an active research site in Nashville, TN that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for leiomyosarcoma treatment options in Nashville, TN, this clinical trial (NCT05653388) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Nashville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced leiomyosarcoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all leiomyosarcoma clinical trials near you to find additional studies recruiting in your area.
See all sarcoma clinical trials recruiting in Nashville — not just this study.
Browse Sarcoma Trials in Nashville →